Clinical Trial Search

Primary: Proportion of Women Who Benefited of Performing Upfront Sentinel Lymph Node (SLN) Biopsy Ductal Carcinoma in Situ — 51 Participants

Primary: Median Change in 6-month Tumor Volume Compared to Baseline Using Mammography — -5.0 change in tumor volume (mm) — p=0.07

Primary: Proliferation (Ki67 IHC) in Ductal Breast Carcinoma In Situ (DCIS)

Primary: Mean Total MRI Functional Tumor Volume (FTV) Change From Baseline to Month 3 (V3) — -1.93 cubic centimeters — p=<0.001

Primary: Ipsilateral Invasive Breast Cancer, Ipsilateral Skin Cancer Recurrence, or Ipsilateral DCIS-Free Survival — 95.1; 96.1 percentage of patients event free

Primary: Number of Participants With Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours — 103; 120 Participants — p=0.33

Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004

Primary: Number of Patients With Pathological Complete Response — 2 participants

Primary: Difference Between Ki-67 Labeling Index in Tissue Samples Taken at Baseline and Post-treatment — -3.4; -5.1 percentage of 300 DCIS cells

Primary: Pathologic Complete Response Rate After Preoperative Therapy in This Patient Population. — 8; 44 percentage of participants

Primary: Association Between Patient Characteristics and Three-Level Cluster of Treatment Intensity for Primary DCIS — 145; 115; 99; 0 Participants — p=<0.05

Primary: Percentage of Patients Free From Breast Cancer — 89.1; 93.1 percentage of participants event-free

Primary: 18F-FES Uptake in DCIS — 1.43 SUV

Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale

Primary: Percent Change in Proliferation as Measured by Ki-67

Primary: Maximum Tolerated Dose (MTD) — 10 milligrams

Primary: Test the Clinical Effectiveness of Concurrent Paclitaxel and Radiation in a Multiethnic Cohort

Primary: Local, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival) — 356; 352 Participants — p=0.978

Primary: Pathologic Complete Response (pCR) — 18 percentage of participants

Primary: Change in Ki-67 Labeling Index — -1.0; -4.8 percent positive cells

Primary: Pathologic Complete Response — 5; 1; 4; 2 Participants

Primary: Endoxifen Concentrations in Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes — 8.4; 10.00; 7.10; 3.42 ng/mL

Primary: Number of Participants Experiencing Acute, Late Skin, and Subcutaneous Toxicity — 0 Participants

Primary: Local Inbreast Breast Tumor Recurrence (IBTR) Rate — 4.3 Percentage of participants with IBTR

Primary: Number of Participants With Adverse Events — 9; 20 Participants

Primary: Percentage of Participants With Pathologic Complete Response (pCR) — 38.9 percentage of participants

Primary: Local Control Rate for Follow-up Period of 5 Years. — 99 percentage of subjects

Primary: The Residual Cancer Burden Grade III (RCB-III). — 23; 37; 14; 6 Participants

Primary: Number of Participants Who Chose Active Monitoring (AM). — 28; 18 Participants

Primary: Side Effects (Claim-based Measure), Including Lymphedema, Seroma, Wound Infection, or Pain — 534; 404; 23; 60 Participants — p=<.001